Published in Hypertension on December 01, 1988
Nitric oxide-mediated hyporeactivity to noradrenaline precedes the induction of nitric oxide synthase in endotoxin shock. Br J Pharmacol (1993) 2.32
Vascular hyporeactivity to vasoconstrictor agents and hemodynamic decompensation in hemorrhagic shock is mediated by nitric oxide. Proc Natl Acad Sci U S A (1993) 1.96
Angiogenesis and rheumatoid arthritis: pathogenic and therapeutic implications. Ann Rheum Dis (1992) 1.65
Tumor necrosis factor alpha activates soluble guanylate cyclase in bovine glomerular mesangial cells via an L-arginine-dependent mechanism. J Exp Med (1990) 1.62
Endothelium-dependent vascular responses. Mediators and mechanisms. J Clin Invest (1989) 1.36
Cigarette smoking, endothelial injury and cardiovascular disease. Int J Exp Pathol (2000) 1.15
Selective impairment of hindquarters vasodilator responses to bradykinin in conscious Wistar rats with streptozotocin-induced diabetes mellitus. Br J Pharmacol (1991) 1.12
Effects of cyclic AMP-affecting agents on contractile reactivity of isolated mesenteric and renal resistance arteries of the rat. Br J Pharmacol (1990) 0.92
Endothelium-dependent increase in vascular sensitivity to phenylephrine in long-term streptozotocin diabetic rat aorta. Br J Pharmacol (1992) 0.90
Different patterns of release of endothelium-derived relaxing factor and prostacyclin. Br J Pharmacol (1992) 0.90
Overview of platelet physiology: its hemostatic and nonhemostatic role in disease pathogenesis. ScientificWorldJournal (2014) 0.90
Vasodilatory effect of arginine vasopressin is mediated by nitric oxide in human forearm vessels. J Clin Invest (1993) 0.89
Proliferation-dependent changes in release of arachidonic acid from endothelial cells. J Clin Invest (1994) 0.89
The PPAR-Platelet Connection: Modulators of Inflammation and Potential Cardiovascular Effects. PPAR Res (2008) 0.85
Endothelial regulation of vascular tone. Postgrad Med J (1992) 0.83
Visualizing novel concepts of cardiovascular calcification. Trends Cardiovasc Med (2013) 0.83
Reactivity and sensitivity of mesenteric vascular beds and aortic rings of spontaneously hypertensive rats to endothelin: effects of calcium entry blockers. Br J Pharmacol (1990) 0.81
Cardiac release of chemoattractants after ischaemia induced by coronary balloon angioplasty. Br Heart J (1993) 0.79
Improved functional vasodilation in obese Zucker rats following exercise training. Am J Physiol Heart Circ Physiol (2011) 0.78
Phospholipase A2-induced pathophysiologic changes in the guinea pig lung. Am J Pathol (1990) 0.78
The hypertensive disorders of pregnancy. BMJ (1995) 0.77
Increased activity of guanylate cyclase in the atherosclerotic rabbit aorta: role of non-endothelial nitric oxide synthases. Br J Pharmacol (1996) 0.77
The use of angiostatic steroids to inhibit cartilage destruction in an in vivo model of granuloma-mediated cartilage degradation. Agents Actions (1993) 0.77
Diabetes mellitus: a prothrombotic state implications for outcomes after coronary revascularization. Vasc Health Risk Manag (2009) 0.77
Mediation of bradykinin-induced contraction in canine veins via thromboxane/prostaglandin endoperoxide receptor activation. Br J Pharmacol (1990) 0.77
Endothelin Receptor Antagonists for the Treatment of Raynaud's Phenomenon and Digital Ulcers in Systemic Sclerosis. Int J Rheumatol (2011) 0.75
Efficacy of treatment with the iron (III) complex of diethylenetriamine pentaacetic acid in mice and primates inoculated with live lethal dose 100 Escherichia coli. J Clin Invest (1996) 0.75
Fibronectin biosynthesis in the rat aorta in vitro. Changes due to experimental hypertension. J Clin Invest (1991) 0.75
Thermography Improves Clinical Assessment in Patients with Systemic Sclerosis Treated with Ozone Therapy. Biomed Res Int (2017) 0.75
Elevated contractile responses to acetylcholine in organ cultured rabbit carotid artery. Yonsei Med J (2006) 0.75
Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol (1971) 37.53
Release of additional factors in anaphylaxis and its antagonism by anti-inflammatory drugs. Nature (1969) 13.60
An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Nature (1976) 13.19
Prostaglandins: their disappearance from and release into the circulation. Nature (1967) 8.66
The release and fate of vaso-active hormones in the circulation. Br J Pharmacol (1969) 7.90
Prostaglandins released by the spleen. Nature (1968) 7.61
Cyclooxygenases 1 and 2. Annu Rev Pharmacol Toxicol (1998) 7.22
Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. Proc Natl Acad Sci U S A (1999) 5.96
Indomethacin and aspirin abolish prostaglandin release from the spleen. Nat New Biol (1971) 5.62
Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. Proc Natl Acad Sci U S A (1993) 4.82
Pressor effects of circulating endothelin are limited by its removal in the pulmonary circulation and by the release of prostacyclin and endothelium-derived relaxing factor. Proc Natl Acad Sci U S A (1988) 4.77
Regulatory functions of the vascular endothelium. N Engl J Med (1990) 4.72
Pharmacology and endogenous roles of prostaglandin endoperoxides, thromboxane A2, and prostacyclin. Pharmacol Rev (1978) 4.66
Arterial walls generate from prostaglandin endoperoxides a substance (prostaglandin X) which relaxes strips of mesenteric and coeliac ateries and inhibits platelet aggregation. Prostaglandins (1976) 4.54
Inactivation of prostaglandins by the lungs. Nature (1970) 4.47
Arterial walls are protected against deposition of platelet thrombi by a substance (prostaglandin X) which they make from prostaglandin endoperoxides. Prostaglandins (1976) 4.44
Human arterial and venous tissues generate prostacyclin (prostaglandin x), a potent inhibitor of platelet aggregation. Lancet (1977) 4.11
Effects of prostacyclin (PGX) on cyclic AMP concentrations in human platelets. Prostaglandins (1977) 3.74
Eicosapentaenoic acid and prevention of thrombosis and atherosclerosis? Lancet (1978) 3.74
The chemical structure of prostaglandin X (prostacyclin). Prostaglandins (1976) 3.63
Effects of anti-inflammatory drugs on prostaglandin biosynthesis. Nat New Biol (1972) 3.54
Inhibition of prostaglandin synthetase in brain explains the anti-pyretic activity of paracetamol (4-acetamidophenol). Nature (1972) 3.30
Arachidonic acid metabolites and the interactions between platelets and blood-vessel walls. N Engl J Med (1979) 3.29
Differential formation of prostacyclin (PGX or PGI2) by layers of the arterial wall. An explanation for the anti-thrombotic properties of vascular endothelium. Thromb Res (1977) 3.28
Prostaglandins, aspirin-like drugs and the oedema of inflammation. Nature (1973) 3.20
A new approach to anti-inflammatory drugs. Biochem Pharmacol (1979) 2.95
Receptor-mediated release of endothelium-derived relaxing factor and prostacyclin from bovine aortic endothelial cells is coupled. Proc Natl Acad Sci U S A (1988) 2.84
Identification of an enzyme in platelet microsomes which generates thromboxane A2 from prostaglandin endoperoxides. Nature (1976) 2.83
Involvement of nitric oxide in the reflex relaxation of the stomach to accommodate food or fluid. Nature (1991) 2.82
The mechanism of action of aspirin. Thromb Res (2003) 2.72
Prostacyclin (PGX) is the endogenous metabolite responsible for relaxation of coronary arteries induced by arachindonic acid. Prostaglandins (1977) 2.67
The metabolism of L-arginine and its significance for the biosynthesis of endothelium-derived relaxing factor: cultured endothelial cells recycle L-citrulline to L-arginine. Proc Natl Acad Sci U S A (1990) 2.63
Pharmacokinetic function of the pulmonary circulation. Physiol Rev (1974) 2.52
The release of prostaglandins and rabbit aorta contracting substance (RCS) from rabbit spleen and its antagonism by anti-inflammatory drugs. Br J Pharmacol (1972) 2.52
Unstable metabolites of arachidonic acid and their role in haemostasis and thrombosis. Br Med Bull (1978) 2.51
Prostaglandins, oxygen tension and smooth muscle tone. Br J Pharmacol (1972) 2.51
Intrarenal prostaglandin release attenuates the renal vasoconstrictor activity of angiotensin. J Pharmacol Exp Ther (1973) 2.48
Imidazole: a selective inhibitor of thromboxane synthetase. Prostaglandins (1977) 2.48
The disappearance of bradykinin and eledoisin in the circulation and vascular beds of the cat. Br J Pharmacol Chemother (1967) 2.44
Release of rabbit aorta contracting substance (RCS) and prostaglandins induced by chemical or mechanical stimulation of guinea-pig lungs. Br J Pharmacol (1973) 2.42
Phospholipase A2 activity of guinea-pig isolated perfused lungs: stimulation, and inhibition by anti-inflammatory steroids. Br J Pharmacol (1978) 2.41
The cell wall components peptidoglycan and lipoteichoic acid from Staphylococcus aureus act in synergy to cause shock and multiple organ failure. Proc Natl Acad Sci U S A (1995) 2.36
The contribution of prostaglandin production to contractions of the isolated uterus of the rat. Br J Pharmacol (1973) 2.33
Nitric oxide-mediated hyporeactivity to noradrenaline precedes the induction of nitric oxide synthase in endotoxin shock. Br J Pharmacol (1993) 2.32
New insights into the mode of action of anti-inflammatory drugs. Inflamm Res (1995) 2.29
A lipid peroxide inhibits the enzyme in blood vessel microsomes that generates from prostaglandin endoperoxides the substance (prostaglandin X) which prevents platelet aggregation. Prostaglandins (1976) 2.28
Conversion of angiotensin I to angiotensin II. Nature (1967) 2.26
Selective inhibition of prostaglandin production in inflammatory exudates and gastric mucosa. Nature (1980) 2.24
Release of prostaglandin E-1 from the rat stomach. Nature (1967) 2.13
Human neutrophils and mononuclear cells inhibit platelet aggregation by releasing a nitric oxide-like factor. Proc Natl Acad Sci U S A (1989) 2.08
Prostaglandins and the mechanism of analgesia produced by aspirin-like drugs. Br J Pharmacol (1973) 2.07
The effects of prostagladin endoperoxides and thromboxane A2 on strips of rabbit coeliac artery and certain other smooth muscle preparations [proceedings]. Br J Pharmacol (1976) 2.06
The release of catechol amines from the adrenal medulla by histamine. Br J Pharmacol Chemother (1965) 2.00
Vascular hyporeactivity to vasoconstrictor agents and hemodynamic decompensation in hemorrhagic shock is mediated by nitric oxide. Proc Natl Acad Sci U S A (1993) 1.96
Rat endothelin is a vasodilator in the isolated perfused mesentery of the rat. Eur J Pharmacol (1989) 1.95
Fate of angiotensin I in the circulation. Nature (1968) 1.94
Endothelial cells metabolize NG-monomethyl-L-arginine to L-citrulline and subsequently to L-arginine. Biochem Biophys Res Commun (1990) 1.94
Metabolism of the angiotensins in isolated perfused tissues. Nature (1969) 1.91
5-hydroxytryptamine in the circulation of the dog. Nature (1967) 1.88
The distribution and metabolism of arachidonic acid in rabbit platelets during aggregation and its modification by drugs. Br J Pharmacol (1977) 1.87
Comparison of the effects of prostacyclin (PGI2), prostaglandin E1 and D2 on platelet aggregation in different species. Prostaglandins (1978) 1.85
Comparison of the vasodepressor effects of prostacyclin and 6-oxo-prostaglandin F1alpha with those of prostaglandin E2 in rats and rabbits. Br J Pharmacol (1978) 1.85
Induction of cyclo-oxygenase-2 by cytokines in human pulmonary epithelial cells: regulation by dexamethasone. Br J Pharmacol (1994) 1.82
Proceedings: Prostaglandin generation maintains the smooth muscle tone of the rabbit isolated jejunum. Br J Pharmacol (1972) 1.80
The detection and estimation of bradykinin in the circulating blood. Br J Pharmacol Chemother (1967) 1.80
Pharmacokinetics of aspirin and salicylate in relation to inhibition of arachidonate cyclooxygenase and antiinflammatory activity. Proc Natl Acad Sci U S A (1987) 1.80
The effects of alteration of blood-volume on the concentration of circulating angiotensin in anaesthetized dogs. J Physiol (1966) 1.66
Partial purification of rabbit aorta contracting substance-releasing factor and inhibition of its activity by anti-inflammatory steroids. Nature (1976) 1.65
The generation from arachidonic acid of rabbit aorta contracting substance (RCS) by a microsomal enzyme preparation which also generates prostaglandins. Br J Pharmacol (1972) 1.65
Co-induction of nitric oxide synthase and cyclo-oxygenase: interactions between nitric oxide and prostanoids. Br J Pharmacol (1995) 1.63
Prostacyclin is a circulating hormone. Nature (1978) 1.60
Synthesis of 6-keto-PGF1alpha by ram seminal vesicle microsomes. Prostaglandins (1977) 1.57
Prostaglandin endoperoxide and thromboxane generating systems and their selective inhibition. Prostaglandins (1976) 1.56
The mode of action of aspirin and similar compounds. J Allergy Clin Immunol (1976) 1.52
Inhibition of the activity of poly(ADP ribose) synthetase reduces ischemia-reperfusion injury in the heart and skeletal muscle. Proc Natl Acad Sci U S A (1997) 1.52
Endothelium-derived relaxing factor reduces platelet adhesion to bovine endothelial cells. Proc Natl Acad Sci U S A (1988) 1.51
Mediation via different receptors of the vasoconstrictor effects of endothelins and sarafotoxins in the systemic circulation and renal vasculature of the anaesthetized rat. Br J Pharmacol (1993) 1.51
Effects on smooth muscle preparations of unidentified vasoactiv peptides from intestine and lung. Nature (1970) 1.51
Pharmacodynamic profile of prostacyclin. Am J Cardiol (1995) 1.51
Eicosanoids in inflammation. Ann Clin Res (1984) 1.50
Osteoclastic inhibition: an action of nitric oxide not mediated by cyclic GMP. Proc Natl Acad Sci U S A (1991) 1.50
Anti-inflammatory drugs and their mechanism of action. Inflamm Res (1998) 1.48
Rapid reduction of prostaglandin 15-hydroxy dehydrogenase activity in rat tissues after treatment with protein synthesis inhibitors. Br J Pharmacol (1975) 1.48
Prostaglandins as mediators of inflammation. Adv Prostaglandin Thromboxane Res (1976) 1.48
The effects of non-steroid anti-inflammatory drugs on leukocyte migration in carrageenin-induced inflammation. Eur J Pharmacol (1980) 1.48
Some effects of inhibiting endogenous prostaglandin formation on the responses of the cat spleen. Br J Pharmacol (1973) 1.47
Endothelin-1 and endothelin-3 release EDRF from isolated perfused arterial vessels of the rat and rabbit. J Cardiovasc Pharmacol (1989) 1.45
The metabolism of L-arginine and its significance for the biosynthesis of endothelium-derived relaxing factor: L-glutamine inhibits the generation of L-arginine by cultured endothelial cells. Proc Natl Acad Sci U S A (1990) 1.43
Mechanism of action of nonsteroidal anti-inflammatory drugs. Am J Med (1998) 1.41
The continuous estimation of angiotensin formed in the circulation of the dog. J Physiol (1966) 1.41
Genetic hypertension in rats is accompanied by a defect in renal prostaglandin catabolism. Nature (1976) 1.41
Role of tumour necrosis factor in the induction of nitric oxide synthase in a rat model of endotoxin shock. Br J Pharmacol (1993) 1.40
Polymorphonuclear leukocytes produce thromboxane A2-like activity during phagocytosis. Prostaglandins (1976) 1.40
Actions of prostacyclin (PGI2) and its product, 6-oxo-PGF1alpha on the rat gastric mucosa in vivo and in vitro. Prostaglandins (1978) 1.39
The release of rabbit aorta contracting substance (RCS) from chopped lung and its antagonism by anti-inflammatory drugs. Br J Pharmacol (1970) 1.38
Further studies on the enzymatic conversion of prostaglandin endoperoxide into prostacyclin by porcine aorta microsomes. Biochim Biophys Acta (1978) 1.37
The effects of antiinflammatory drugs on the production of prostaglandins in vivo. Adv Prostaglandin Thromboxane Res (1976) 1.36
Inhibition of prostaglandin biosynthesis. Biochem Pharmacol (1974) 1.34
Induction of an acetaminophen-sensitive cyclooxygenase with reduced sensitivity to nonsteroid antiinflammatory drugs. Proc Natl Acad Sci U S A (1999) 1.34